Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Stuart M. Grant Acquires 100,000 Shares of Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was bought at an average price of $0.98 per share, with a total value of $98,000.00. Following the transaction, the insider now directly owns 5,430,715 shares in the company, valued at $5,322,100.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eyenovia Price Performance

NASDAQ EYEN opened at $0.99 on Friday. The company has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $1.60. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.17 and a quick ratio of 2.16. Eyenovia, Inc. has a 52-week low of $0.92 and a 52-week high of $5.85.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). During the same quarter in the previous year, the business earned ($0.17) earnings per share. Research analysts anticipate that Eyenovia, Inc. will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyenovia

A number of hedge funds have recently added to or reduced their stakes in the company. Leo Wealth LLC acquired a new position in Eyenovia in the fourth quarter worth approximately $34,000. Vanguard Group Inc. increased its holdings in Eyenovia by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,429,577 shares of the company’s stock worth $2,974,000 after buying an additional 61,732 shares during the last quarter. Virtu Financial LLC acquired a new position in Eyenovia in the fourth quarter worth approximately $26,000. Barclays PLC increased its holdings in Eyenovia by 663.9% in the fourth quarter. Barclays PLC now owns 41,390 shares of the company’s stock worth $86,000 after buying an additional 35,972 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Eyenovia by 4.9% in the fourth quarter. Northern Trust Corp now owns 253,250 shares of the company’s stock worth $527,000 after buying an additional 11,757 shares during the last quarter. Institutional investors and hedge funds own 25.84% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a research report on Tuesday, March 19th.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.